Evidence map›Paper›PMID 34071269›Full record

ArticleMolecules (Basel, Switzerland)2021

5-HT

Nazlı Turan Yücel, Ümmühan Kandemir, Ümide Demir Özkay, Özgür Devrim Can

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. VortioxetineCurrent neuropharmacology · 2025
    Trial
  2. Article
  3. Article
  4. DecipheringAdvances in pharmacological and pharmaceutical sciences · 2024
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Nazlı Turan YücelDepartment of Pharmacology, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey.ORCID 0000-0002-0371-2703
Ümmühan KandemirDepartment of Pharmacology, Institute of Health Sciences, Anadolu University, Eskişehir 26470, Turkey.ORCID 0000-0003-3314-1961
Ümide Demir ÖzkayDepartment of Pharmacology, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey.
Özgür Devrim CanDepartment of Pharmacology, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey.
Anadolu University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vortioxetine is a multimodal antidepressant drug that affects several brain neurochemicals and has the potential to induce various pharmacological effects on the central nervous system. Therefore, we investigated the centrally mediated analgesic efficacy of this drug and the mechanisms underlying this effect. Analgesic activity of vortioxetine (5, 10 and 20 mg/kg,

Indexed as

alpha-MethyltyrosineAnalgesiaAnalgesicsAnalgesics, OpioidAnimalsBrainDiazepamFenclonineMaleMaze LearningMiceMice, Inbred BALB CMorphineMotor SkillsNaloxonePain1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazinealpha-MethyltyrosineAnalgesicsAnalgesics, OpioidDiazepamFenclonineMorphineNaloxonePhentolaminePiperazinesReceptors, Adrenergic, alphaReceptor, Serotonin, 5-HT1ASelective Serotonin Reuptake InhibitorsSerotonin 5-HT1 Receptor AgonistsVortioxetinehot-plate testmonoaminesopioidtail-clip testtail-immersion testvortioxetine

Identifiers

PMID34071269
PMCPMC8199248
OpenAlexW3165107623

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.